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Summary
An overview of the links between the Hypothalamic-Pituitary-Adrenal (HPA) axis and psychiatric
disorders is presented. The current treatments are outlined, indicating that they are insufficient to
meet the needs of those that suffer from these affective disorders. Therefore, there is an urgent need
for the generation of new therapeutics, in particular, against new targets. The association of the
corticotrophin releasing factor (CRF) and the HPA axis indicates that CRF antagonists should be
beneficial as potential therapeutics.

Introduction
It is estimated that 22% of Americans aged 18 years and older suffer from some form of
diagnosable mental disability [1]. Of the 10 leading causes of disability in the US, four are
psychiatric diseases and include unipolar disorder (UPD), bipolar disorder (BPD), anxiety and
anorexia nervosa [2]. These figures have been mirrored in other developed countries such as the
United Kingdom and Australia where approximately 20% of the adult population suffer from some
form of psychiatric disability [3].
Current treatments for these conditions are barely adequate and there is the need for the
development of a new generation of novel psychiatric pharmaceutical agents acting via alternate
mechanisms. Several new hypotheses have been formulated in recent times in response to the
ongoing inadequacy of current psychiatric treatments. Many of these directly suspect the
dysregulation of the bodies stress system, the hypothalamic-pituitary-adrenal (HPA) axis, as being
responsible for the induction and prolongation of psychiatric diseases [4]. Subsequently these
hypotheses have implicated the HPA axis components; corticotropin-releasing factor (CRF),
glucocorticoids and cyclic adenosine monophosphate (cAMP) response element binding proteins
(CREB) as subsystems that are potentially responsible for psychiatric malfunctions [5].
Although the HPA axis has been studied extensively since the 1950’s, only recent breakthroughs in
biotechnology and endocrinology have resulted in the successful cloning of CRF and its receptors
[6]. Thus allowing the means to closely study and monitor their characteristics.
Recent studies [7] analysing the HPA axis and its involvement in psychiatric diseases have
identified the following unusual symptoms in patients; high concentrations of CRF in the central
nervous system (CNS), abnormal results to corticoid response tests, hyperactive CRF neuron
activity and abnormal CRF receptor expression patterns. This has justified initial scientific efforts to
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look more closely at the role of CRF in the induction HPA dysregulation [7]. The increasing
evidence that CRF and the HPA axis play definitive roles in many psychological disabilities has led
to a focus on CRF antagonists as a novel means to treat these disorders [8].
This review will discuss the current knowledge of CRF and its receptors, examine evidence put
forward to support the CRF-HPA dysregulation hypothesis while finally commenting on recent
developments in CRF antagonist research.

Psychiatric Disabilities
Undoubtedly an extensive range of psychiatric conditions will potentially benefit from CRF based
antagonist treatment. Even though a wide range of psychiatric disorders exist, discussion will focus
on affective, anxiety and narcotic dependence based conditions.

Affective disorders:
Affective disorders are the most common form of psychiatric condition present in modern day
society [9]. While often being a preluding or partnered condition for numerous other disorders such
as drug addiction, obsessive compulsive disorder (OCD), anxiety and anorexia, affective disorders
are generally classified as depression, which is further divided into two subtypes; bi-polar and unipolar disorders.
Bi-polar disorder, more commonly known as manic depression, is a form of mood disorder
characterised by brief periods of euphoria followed by alternating periods of severe depression. The
manic or euphoric phases are characterised by extreme hyperactivity, restlessness and feelings of
great self importance often accompanied by a denial of their condition [7, 9, 10]. The disease occurs
in approximately 1.6% of the world population and is diagnosed equally between men and women
[10].
Uni-polar depression differs from its bi-polar counterpart as no mania spells are experienced by the
patient. Depressive episodes follow a more continuous unrelenting pattern with intermittent periods
of normal emotional behaviour. Additional symptoms include torpidity due to diminished energy
levels, low self esteem and reduced motivation to partake in normal activities [7, 9]. This can lead
to a breakdown of social and family ties and reduced productivity in the workforce, with an
estimated cost in the US alone of $55 billion per year arising from depression-related illnesses [10].
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Anxiety:
Anxiety disorders encompass a wide range of conditions such as general anxiety disorders (GAD),
panic disorder, post traumatic stress disorder, phobias and Tourette syndrome [9, 11]. These
disorders are characterized by patients experiencing fear or constant episodes of anxiety over
matters which do not necessarily require or provoke any real cause for anxiety. Anxiety disorders
cause symptoms such as chest pains, dizziness and hot flashes during panic attack episodes,
increased heart rate, poor concentration and irrational behaviour. One in every eight Americans
aged 18-54 suffers from an anxiety disorder [7], with these statistics being mirrored in other
developed nations.

Substance abuse:
Drug addiction is defined as the uncontrollable desire to take a drug accompanied by diminished
control in limiting its intake [12]. Drug addiction, also known as drug dependency, can involve both
physiological and psychological dependence. Physiological dependence is caused by alterations to
the user’s physiology and metabolic pathways resulting in adaptation requiring the drug to be
present for continued function. Psychological dependence is when patients assume they need a drug
in order to properly function where in fact no physiological dependence exists [11, 12]. Drug
addiction is usually more prevalent in males than females however the incidence of female
addiction is rising [12].
Narcotic addiction or dependence can result in increased tolerance barriers by physiological
adaptations by the brain, e.g. desensitisation through reduction in receptor populations [13].
Unfortunately this can lead to the use of high doses of narcotic substances which can give rise to
permanent organ damage and/or death. Some of the known addiction or dependency side effects
include; social isolation, poor concentration, aggressive behaviour and irrational thinking.
In the US, 23 million adults are believed to be repeat substance offenders [7, 10]. Drug addiction in
the US is estimated to cost over $67 billion dollars a year in social and medical costs for treatment
of illicit drug users [12].
In summary affective, anxiety and substance abuse are three classes of psychiatric disorders with
unique mechanisms. There is growing evidence to support that these three conditions share a
common involvement of CRF and the HPA.

Current Treatments of Psychiatric Disorders
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Current treatments have been designed according to the monoamine theory, whereby focus is placed
on regulating the production and reuptake of neurotransmitters such serotonin, norepinephrine and
dopamine, which have been attributed to play a significant role in depression [14]. Unfortunately, as
well as being effective, these agents also have numerous limitations. Initial treatment only cures
approximately 50% of patients with one in three not responding to standard treatments in the long
term [15].
Selective Serotonin Reuptake Inhibitors (SSRIs) are currently the most prescribed drug family for
treatment against depression and anxiety related illnesses [16]. Typically SSRI drug therapy takes
4-6 weeks to show any positive results, and is preferred for depression patients as the risks
associated with overdosing are greatly reduced [16, 17]. Once symptoms subside, antidepressant
therapy is continued for up to 6-9 months [15-17]. Such lengthy medication regimes are expensive
and patient discipline in continuing treatment for this long can waver [16]. SSRI regimes are
unfortunately associated with draw backs such as nausea, insomnia, and low libido which can
impede sexual functions [18].
Monoamine Oxidase Inhibitors (MAOIs) were the first antidepressants introduced into mainstream
society and have also been adopted to treat anxiety patients. These drugs are still considered
secondary option treatments for patients whom fail to respond to alternative first wave therapeutics
for anxiety and depression [16]. MAOIs initiate the rapid and sustained release of serotonin (5-HT)
in the brain by inhibiting monoamine oxidase. Common side effects associated with MOAI therapy
are; hypotension, tremors, insomnia, convulsions while in some cases they can induce dangerous
drug-to-drug and drug-food interactions causing serious harm [18,19]. As a result patients are often
forced to comply with strict diets and are prevented from taking many other pharmaceutical agents
[19].
Tricyclic antidepressants (TCA) drug therapy is known to have similar results to SSRI treatments
[17], however they usually require a longer period for their onset of action compared to SSRI based
drugs [15]. Their method of action is primarily to prevent the reuptake of amines by nerve
terminals. TCA therapies typically cause blurred vision and constipation. In addition, patients with
heart complications are strictly prohibited from using these drugs as they can cause arrhythmias
[20].
Beta-Blockers and benzodiazepines are fast-acting short term anxiety treatment options requiring
unfavourable repeated dosing applications to prolong therapeutic effects [16]. Beta-Blockers are not
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prescribed to patients with asthma or heart complications as they can amplify these conditions [21].
Benzodiazepines are addictive and cause drowsiness, fatigue and poor memory making their usage
highly unfavourable [22].

Corticotropin Releasing Factor (CRF)
CRF is the hypothalamic peptide Fig. (1) that stimulates adrenocorticotropin hormone (ACTH)
release from the pituitary gland which in turn induces cortisol release as a mechanism for organisms
to deal with stress inducing situations [23]. CRF is a small 41 amino acid peptide synthesized and
released from multiple regions of the brain including the paraventricular nucleus (PVN),
hypothalamus and the locus ceruleus (LC) [24]. CRF is the initiator of the HPA axis and determines
the rate at which the HPA axis operates. This peptide has also been associated with secondary roles
such as the regulation of proopiomelanocortin (POMC) and other neuronal peptides. [25]
H-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-MetThr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2
Figure 1: Amino acid sequence of CRF.

Distribution of CRF:
CRF synthesis and storage bodies are densely populated within the paraventricular nucleus (PVN)
of the hypothalamus and amygdala [26]. Production of CRF is stimulated through various neuronal
peptides and transmitters including acetylcholine, histamine, serotonin and many other common
neuronal messengers [27]. The PVN and amygdala neuronal bodies distribute their axons to the
capillaries in the median eminence, lower brain steam, cerebral cortex and spinal cord [28]. High
concentrations of CRF are present in the locus caeruleus and the central nucleus of the amygdala,
both of which are involved in anxiety and stress behaviour regulation and are stimulated by CRF
neurons in the PVN. [4, 23, 29]. Additional CRF containing bodies are present in the neocortex and
bed nucleus of the stria terminalis [29].
Peripheral tissues including the stomach, pancreas, small intestine, lymphocytes, placenta and the
testes also have demonstrated a significant CRF presence [23]. The identification of CRF in these
non-CNS neuronal bodies suggests its wide range of influence in numerous physiological systems
such as immunity, digestion and reproduction in addition to the stress axis [26-28].
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CRF Receptors:
Currently 2 types of CRF receptors have been classed and identified, CRF1 receptors (CRF1R) and
CRF2 receptors (CRF2R). Both receptors have their own unique gene and custom distribution within
the body. CRF1R and CRF2R both share close homology with one another and belong to the class B
subtype of G-protein coupled receptors Fig. (2) [28].

Figure 2: Amino acid sequences for corticotropin releasing hormone CRF1, CRF2α, CRF2β and
CRF2γ receptor types. The seven transmembrane domains are shown where the arrows indicate the
divergence between the CRF1 and the various CRF2 receptors. Glycolysation sites have been
indicated by ψ while ▲ indicate protein kinase C binding sides.

The third intracellular loop within all CRF receptors is thought to be the interactive region between
the receptor and the coupled G-protein. This hypothesis is supported by the fact that the third
intracellular loop is identical across all isoforms of the CRF receptor [26, 28]. CRF receptors are
positively regulated via cAMP accumulation in response to CRF agonist binding which then relays
the hormonal signal [29].

CRF1 receptors (CRF1R):
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The CRF1R is 415 amino acids in length, its seven transmembrane domains contain 5 N-linked
glycolysation sites and 2 potential phosphorylation sites for protein kinase C (PKC) in the Cterminal tail. CRF1R also has casein kinase II and protein kinase Fig. (2). A phosphorylation sites in
the 3rd extracellular loop, however their purpose remains unclear [30]. A variety of CRF1R spliced
variants exist and have been classified CRF1a through to CRF1h [4]. These variants have not shown
any significant alternative activity compared to CRF1aR [4].
CRF1R shows high distribution within the brain and other sections of the CNS. Most dense areas of
distribution are in the cerebral cortex, olfactory bulb, medial septum, hippocampus, amygdala and
the pituitary [29, 31, 32]. Through autoradiography localisation studies it has been discovered that
CRF1R distribution patterns in different compartments of the brain vary [31]. For instance CRF1R
within the anterior pituitary seem to be clustered, mirroring the distribution of corticotrophs. This
contrasts CRF1R distribution within the intermediate lobe where the receptors are localised evenly
across the lobe, following the distribution patterns of POMC producing cells. [33]
The distribution patterns of CRF1R within the brain and peripheral tissues support current
hypotheses suggesting CRF is responsible for POMC peptide regulation and secretion from the
anterior and intermediate pituitary lobes [23, 33].

CRF2 Receptors (CRF2R):
The second splice variant of the CRF receptor family, CRF2R, can be subdivided into 3 isoforms
CRF2α CRF2β and CRF2γ. Both α and β isoforms have been isolated in rats, mice and humans
however CRF22γR has only been identified in humans [26, 34].
CRF2 receptors, unlike their CRF1R counterparts, have a wide distribution, encompassing a broader
range of tissues. Studies showed CRF2R mRNA is expressed in the lateral septal nuclei,
hypothalamic nuclei, in the bed nucleus of the stria terminals along with amygdaloid nuclei, though
not at the same intensity as CRF1R [31]. Furthermore these studies went on to establish that CRF2γR
are distributed mainly in areas of the CNS whereas the CRF2αR and CRF2βR have been identified
primarily in non-neuronal and peripheral tissues such as the cerebral arterioles and the choroid
plexus of the ventricular system [34]. CRF2βR are also found in the heart, GI tract, skeletal muscle
and lungs [4, 23]. Due to the dense distribution of CRF2βR within the cerebral arterioles and the
choroid plexus of the ventricular system it leads to the potential hypotheses that CRF2βR are in fact
linked to a modulation role for cerebral blood flow [33].
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CRF from gene to protein:
The human CRF gene is assembled by 2 exons 686-800 base pairs in length and has been mapped
on Chromosome 8 (8q13) [23]. The translation of the CRF gene produces a 196 amino acid (aa)
pre-proCRF molecule which is enzymatically treated within the rough endoplasmic reticulum to
form proCRF which undergoes additional post-translational alterations [35, 36]. Further alterations
are performed in the trans-Golgi network to produce the final 41 aa CRF peptide [36].
CRF production is regulated through the protein kinase pathway. Studies where cAMP has been
administered to perfused rat hypothalami have shown marked increases in CRF secretion [31].
cAMP is thought to interact with a cAMP responsive element (CRE) region approximately 200 base
pairs upstream from the CRF gene, promoting gene translation [35, 36]. Examination of CRF and
the HPA axis has shown that CRF initiated release of glucocorticoids from the adrenal glands
results in a negative feedback regulation mechanism, where glucocorticoids inhibit CRF production
by interfering with cAMP-response element binding protein CREB/CRE controlled gene
transcription process [35-37].

HPA Axis and stress response:
The HPA axis is the infrastructure of the body which regulates the stress response. CRF neurons
within the PVN of the hypothalamus are the primary source of CRF within the CNS. Release of
CRF stimulates the anterior pituitary to release ACTH, which is transported through the blood
stream to the adrenal cortex to initiate the synthesis and secretion of cortisol, a glucocorticoid [38].
Regulation of the HPA axis is controlled by an intricate network of neuronal and hormonal
pathways including the hippocampus, the amygdala, glucocorticoid peptides and monoamine
neurotransmitters [38, 39]. Activation of the HPA axis results in higher locomotive activity, reduced
sex drive, low affinity for food, redirected blood flow from the gastro intestinal tract to skeletal
muscle, increased sensory sensitivity, increased heart rate and raised blood sugar levels. These
adaptations which help an individual respond to a stress event [39, 40].
A stress event lasting longer than a few minutes results in increased levels of cortisol being released
from the adrenal cortex. CRF and ACTH in healthy individuals are released only in short
intermittent bursts resulting in controlled cortisol release [41]. Thus, in stressful situations, a
moderate cortisol level is maintained in the bloodstream to main stable physiological function and
homeostasis in the HPA axis [41].
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A stress event may be emotionally, physically or chemically induced which initiates CRF secretion
over the affected time period, allowing for beneficial physiological adaptations i.e. increased
sensory sensitivity which allows individual organisms to respond adequately to a stressful situation
[39]. Prolonged stress influences are thought to over-stimulate the HPA axis causing hypersecretion
of CRF which ultimately, if left untreated, leads to HPA dysregulation potentially promoting the
onset of psychiatric disorders [41].

Support for HPA Dysregulation Theory
Numerous studies have indicated that individuals suffering from anxiety and/or depression possess
a sustained unregulated HPA axis. The hyperactivity of the HPA axis has been shown to exacerbate
the additional secretion of CRF and subsequently ACTH. This dysregulation is the assumed cause
of hypercortisolemia, a symptom observed in numerous psychiatric related disabilities [38].

Post Mortem Examinations:
Post mortem analysis of brain tissues obtained from suicide victims who were suffering from long
term depression showed a significant reduction in CRF receptor sites in various regions of the brain,
most noticeably in the cerebral cortex [4]. The emerging pattern of reduced receptor sites suggested
the presence of a mechanism attempting to compensate for the hypersecretion of CRF [42]. Further
study into this phenomenon led to the discovery that suicide victims also had a 400% increase in
CRF producing neurons within the PVN and a dramatic increase in CRF mRNA expression
compared to standard controls [43]. Therefore a mechanism in depressed patients exists which is
responsible for the recruitment of additional neuronal cells to produce CRF. This suggests
dysregulation in the HPA axis as CRF secretion is uninhibited in these patients [44]. Such drastic
increases of CRF secretion would no doubt lead to higher concentrations of ACTH and cortisol in
the blood stream and CNS.

CRF in cerebral spinal fluid (CSF) and blood plasma:
Following initial indications that CRF might be involved in depression and anxiety disorders [45]
further analyses of CRF concentrations were employed. Due to the difficulty of obtaining CRF
concentration data directly from the brain, cerebral spinal fluid (CSF) was used to gauge CRF
concentrations where a clear correlation between diseased states and CRF concentrations in the CSF
was established [46]. Results showed there was a tangible increase in CSF CRF concentrations in
patients who were suffering from depression, anxiety and dementia when compared to healthy
controls [45, 46]. In addition results have also indicated increased levels of CRF in the blood stream
among depressed patients [23], however these results have not been replicated in follow up studies
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[33, 45-46]. The increased amount of CRF discovered in varying bodily fluid systems across
different psychiatric diseases suggests the presence of CRF hypersecretion, thus indicating a
dysregulated HPA axis.

Anxiety effects of CRF:
CRF neurons are believed to encompass numerous additional functions including the influence on
proopiomelanocortin (POMC) synthesis through the release of CRF into the portal blood stream
[47]. POMC is converted to melanocortin which is known to inhibit feeding behaviour and induce
weight loss [47-49]. When an excess of POMC is produced the side effects mimic those observed in
anorexia nervosa patients [47-49]. Observation of rats undergoing chronic exposure to CRF
indicated the manifestation of several response adaptations including hyperexcitability, fear and
other anxiogenic behaviours normally associated with anxiety [50-52]. These initial trials were then
further extended by injecting urocortin, a CRF receptor agonist, into central nucleus of the
amygdala, hypothesised as being the key body involved in signal transmissions responsible for the
onset of anxiety disorders [51]. Results provided evidence of severe anxiogenic symptoms as a
direct result of the chronic agonist exposure.
Antisense oligodeoxynucleotide (ODN’s) tests provided the opportunity to observe if non-CRF
producing rats were still liable to suffer from stress or anxiety behaviour [53]. ODN exploited rats
had significantly decreased anxiety like behaviour and showed a reduction in stress. In reply to
these investigations an alternative approach was trialled whereby CRF was over-expressed using
transgenic mice, mimicking the excess CRF secretion causing HPA dysregulation as observed in
psychiatric patients. As expected, the over-production of CRF in the transgenic mice caused severe
anxious behaviour [52-53]. Extended trials then observed the effect of CRF antagonists upon these
test subjects. As hoped a reversal of anxiety and depression symptoms occurred [23, 33]. By
creating a CRF hypersecretion model in rodents reflecting human observations, these experiments
were able to provide strong supporting evidence linking anxiety to HPA-CRF dysregulation.

Effects of current pharmaceutical agents on CRF:
It has been indicated that current antidepressants may produce their therapeutic effects partly
through the regulation of the HPA-CRF system [14]. Such a hypothesis was first considered when
exposing rats to imipramine, a tricyclic antidepressant (TCA) and CP-154526, a CRF1R antagonist,
resulted in decreased immobility indicating a reduction of CRF influence was linked to a reversal of
anxiety and depression through classical treatments [20]. These trials were further expanded where
it was discovered that rats which had undergone imipramine treatment for two weeks showed signs
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of increased glucocorticoid receptor (GR) immunoreactivity [17]. This change allowed for an
increase in the glucocorticoid negative feedback mechanism in the HPA axis resulting in a
reduction of CRF mRNA in various regions of the brain most importantly the hippocampus,
hypothalamus and the pituitary [40].
Additional evidence proposing alternate mechanisms of action came to light when high numbers of
CRF receptors were observed in rat brains which had undergone chronic imipramine exposure,
suggesting that CRF production had been impeded, forcing the body to compensate by increasing
binding sites [15, 17]. Alternatively links between antidepressant use and a reduction in CRFR in
the anterior pituitary were also established when reductions of CRF1R mRNA expression in the
amygdala was observed in rats after exposure to SSRI treatment [14]. Further studies subsequently
indicated the increase in GR mRNA expression in the hippocampus caused a suspected increase in
HPA axis inhibition as a result of antidepressant usage [16].
Similar studies have been performed on current anti-anxiety treatments, implying they inhibit the
HPA axis. Acute benzodiazepine administration has been shown to result in reduction in CRF
concentration in the locus coeruleus, amygdala and the pyriform cortex, all of which are associated
with stress behaviour [29].
Evidence provided in these monoamine studies has identified many inconsistencies in monoamine
theory, on which most modern day antidepressants and anti-anxiety medications are founded upon
[14, 16]. Most notably, compounds known to significantly enhance monoamine transmission, which
is the suspected mechanism of action of monoamine based treatments, had little to no therapeutic
effect in depressed or anxiety patients. Neurotransmitter concentrations between groups taking
standard medications and the new transmission enhancing drugs were similar, however the new
compounds had no therapeutic effect [14, 16, 17]. This suggests that current antidepressant and
anti-anxiety medications do not enact their therapeutic benefits through monoamine pathways. In
addition it is yet to be explained why certain clinical treatments currently in use show minimal
effects on monoamine transmission pathways, though are potent and therapeutically effective
against depression and anxiety. Furthermore some antidepressant drugs have delayed therapeutic
benefits which, interestingly coincides with an apparent inhibition rather than excitatory effects on
monoaminergic transmission [16].
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These conflicting results suggest that perhaps the current therapies are not primarily enacting their
therapeutic properties through monoamine neuropeptide pathways but also via other mechanisms
related to HPA regulation.

Evidence of HPA dysregulation in substance abusers:
Considerable evidence has indicated that acute administration of psychostimulants causes a stress
like activation of the HPA axis in rodents [54]. Amphetamine exposure tests stimulated high rates
of ACTH release using dosages as low as 6 μg/kg while cocaine induced HPA activation increased
cortisol levels within 10 minutes of injection [54, 55]. Moreover cocaine use in rodents was found
to release CRF from hypothalamic tissue in vitro; this demonstrates that psychostimulant drugs
mediate their effects on the HPA through CRF to induce stress events in the brain. This
subsequently caused abnormal increases of ACTH and cortisol in the CSF and blood stream [54].
Broader studies testing the impact of alcohol and opioids demonstrated similar results suggesting
that many forms of substance abuse cause damage to the HPA system where prolonged exposure
would induce long term HPA dysregulation [12]. Chronic administration of cocaine in subsequent
studies was found to successfully cause HPA over-stimulation implicating the inability of the HPA
axis to raise tolerance response barriers against prolonged cocaine abuse [56]. Protracted use would
likely induce glucocorticoid burden leading to organ system damage as seen in chronic cocaine
users [12].
The initial CRF response to alcohol was a 3 fold increase in CRF concentration in the CSF.
However the development of a tolerance barrier was suspected as PVN CRF neurons showed a
reduction in CRF secretion. This contradicted observations in the pituitary which demonstrated a 2
fold increase in CRF secretion. Conclusions from the study determined that long term alcohol
exposure engendered atypical HPA hyperactivity.
Substance abusers in withdrawal commonly express the symptoms of negative and illogical
behaviour such as dysphoria, depression and irritability. Clinical and non-clinical research has
indicated that stress, depression and negative mood states are strong confounding factors that
increase the likelihood of perpetuation of drug use in substance abusers [12, 57]. Clinical trials
provided circumstantial evidence by demonstrating that heroin experienced mice displayed “drugseeking” behaviour after being exposed to a stress event [55, 57]. Survey statistics established that
many substance abusers were unable to break addictions due to psychological stress, depression and
negative mood states which derived from HPA dysregulation.
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The data obtained from these investigations leads to a theory that substance abuse is potentially a
means of self-medication to stave off depression or negative mood states. Ironically the same
behaviour demonstrated by narcotic addicts increases the stress placed on the brain resulting in a
never ending cycle of CFR secretion and HPA dysregulation [56].

Dexamethasone tests and glucocorticoids:
The condition of hypercorticolism, the hypersecretion of cortisol, is a common trait seen in patients
suffering from depression, anxiety and substance abuse. This condition relates to the abnormal
secretion of cortisol due to excessive CRF activation of the HPA axis. Psychiatric patients
uniformly fail to show any lasting response to the dexamethasone suppression tests which should
inhibit CRF release. This suggests that increased glucocorticoidal concentrations by the introduction
of dexamethasone did not aid in the inhibition of CRF release as expected. Two hypotheses put
forward suggested the potential inception of a yet to be identified resistance mechanism against
standard negative feed-back or the manifestation of an overactive HPA axis resulting in a HPA
drive which was able to easily surpass any cortisol inhibition message [36].
CRF challenge tests were performed by injecting CRF and urocortin, a CRF antagonist into
psychiatric and control patients to analyse the ACTH production response. Results showed diseased
patients had a blunted ACTH response compared to control groups, suggesting that this was caused
by down regulation of the pituitary CRH1Rs in diseased patients as indicated in previous post
mortem studies. Though control groups had higher rates of ACTH synthesis in the short term during
the experiment, diseased patients, still had a higher ACTH secretion rate in the long term due to the
constant hypersecretion of CRF.
Investigations into hypercortisolism and its role in HPA dysregulation revealed that extreme cortisol
concentrations lead to the increased expression of CRF mRNA in the bed nucleus of the stria
terminalis, amygdala and PVN [4, 23]. These results provide a possible explanation for the 400%
increase in CRF secreting neurons observed in the post mortem studies described earlier in this
chapter. These observations that implicate the very pathway meant to inhibit CRF production can be
a contributing instigator of additional CRF secretion. Thus, this suggests the presence of a positive
feedback mechanism promoting HPA dysregulation and hypersecretion of CRF is established in
diseased patients.

Novel CRF antagonists
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With the wealth of evidence that has amassed implicating the role of the HPA-CRF system in the
pathogenesis of affective, anxiety and drug related psychiatric conditions, attention has turned to
seek a new generation of pharmaceutical agents targeting CRF receptors. The structural entities that
possess CRF antagonistic activity have been reviewed,[58,59,60] however some of the more
common and important are summarised here.
Initial attempts at CRF antagonist development resulted in the discovery of the oxopyrazoline
thiocyanates (I) Fig. (3) [61], which showed weak activity against CRF (3-70 mM/L). Further
adaptations led to the development of five-membered ring systems focusing on the thiazole core (II,
III) Fig. (3) framework which has resulted in improved activity (15 nM/L) [61]. Improvements
were also achieved via the addition of quinoline and other bulky side groups dramatically enhancing
activities.

Figure 3: Examples of CRF antagonists containing a five-membered heterocyclic core unit.
CP-154,526 (IV) Fig (4) was the first potent non-peptide CRF1R specific antagonist to be
developed [62]. This antagonist has demonstrated a binding preference for CRF1R having a binding
activity of 2.7 nmol/L when tested in rat PVN neuronal tissue. Trials using this antagonist have
shown it to be a potent inhibiter of CRF activation on the HPA axis reducing stress responses and
also attenuating drug seeking behaviour in rodents [61] and human trials of this compound are
imminent.
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Figure 4: Selective CRF1R antagonists CP-154,526 (IV) and R121929 (V)
These alternative additional fused six-membered ring systems, namely aniline-pyrimidines
structures such as R121919 (V) Fig (4) is a selective CRF1R antagonist which has shown
remarkable benefits over previously synthesised compounds in its class due to increased solubility
and its capacity to easily penetrate the blood brain barrier [63, 64]. Human clinical trials have
shown that this compound improves anxiety and depression states. Clinical trials also provided
evidence indicating its ability to attenuate HPA axis hyperactivity while not entirely inhibiting
ACTH or cortisol release allowing for regular HPA related functions to continue unhampered [63,
64]. Beneficial outcomes have allowed R12919 (V) to move on to larger clinical trials however,
these were discontinued due to hepatoxicity. [65] Research into the CRF and the HPA axis
continues with initial steps giving more support to the HPA dysregulation hypothesis.

Conclusion
Compounding evidence from a wide range of pre-clinical and clinical studies has produced support
for the HPA axis hypothesis suggesting hypersecretion of CRF has a profound effect in initiating
psychiatric disabilities ranging from affective disorders to substance abuse. The source of increased
CRF has been delegated to the hyperactivity of CRF releasing neurons within the amygdala, PVN
and the pituitary causing increased rates of ACTH and cortisol secretion in rodents, primates and
humans. In reply to these results drug developers have shown that experimental CRF antagonists
might provide alternative therapeutic agents through regulation of the HPA axis.
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